A top Food and Drug Administration (FDA) official said on Thursday that the agency is exploring “what flexibilities we might have” when it comes the federal government’s marijuana scheduling review directed by President Joe Biden, which she described as a “very high priority.” But she said that while FDA will lead the scientific and medical … Continue reading FDA Exploring ‘Flexibilities’ In Marijuana Scheduling Review, But Top Official Says DEA Has ‘Final Word’